On December 18, 2020, Hipro biotechnology Corp announced the completion of the c-round financing of over 100 million YUAN!

This round of investment by SDIC will help the industrialization of liquid-phase microfluidic biochip products, accelerate the development of microfluidic iterative products, and promote the construction of company marketing channels and overseas network construction.

Jian Ren, executive director of SDIC, said, “We believe that microfluidics is a disruptive technology in the industry and has broad market prospects. As a pioneer in China's POCT market, Hipro has rich industrialization experience and technological strength to promote the realization of goals. With a keen insight into the international perspective, it has advanced layout, occupying the development opportunity of the microfluidic industry and has achieved phased results. We believe that, in the process of promoting the industrialization of the project, with the support of the company’s excellent scientific research and management team and the industrial ecosystem of SDIC investment, Hipro will give full play to the advantages of the core competitiveness of its products, achieve leapfrog development, and occupy an important pole in the field of precision diagnosis in China.

Shushun Hao , Chairman of Hipro, said, “ the company's stand-out depends on its clear positioning and technical advantages. Hipro has a clear strategic positioning and development path, 14 years of deep plowing layout of POCT, construction of sampler to microfluidic platform, providing integrated solutions for clinical and customers. Through the integration of technology and market, innovation and industry connection, an industrial symbiosis system has been created, and value can be continuously created and improved in terms of technical efficiency and cost realization. Microfluidics is a high-quality track. Fortunately, we have reached a consensus on many development directions with SDIC Investment. Regardless of industrial development and technical strength, we have all the confidence to the capital and science and technology combined with the energy to the maximum, with outstanding product force to promote the application of the microfluidic technology in the world, create more value for the industry development.

Hipro biotechnology Corp, founded on September 29th, 2006, is a high-tech enterprise based on international advanced medical technologies and brilliant self-innovations to provide first class products all over the world. Hipro focuses on R&D, manufacturing, marketing, and relevant services of Point-of Care products. Hipro, with her  reagent R&D Center at Silicon Valley,USA and instrument R&D Center at Freiburg,Germany and production base in China - Hebei Province, has established branches in San Francisco, Freiburg, Beijing, Suzhou, Chengdu, Guangzhou etc., and launched 3.69 acres industrial park project in China Medical City.